MR Spectroscropy and Imaging in Head and Neck Tumors

头颈肿瘤的磁共振波谱学和成像

• 批准号: 6888273
• 负责人: Harish Poptani
• 金额: $ 29.24万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-06-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6888273
• 关键词: bioimaging /biomedical imaging; choline; clinical research; head /neck neoplasm; human subject; human therapy evaluation; image enhancement; lactates; magnetic resonance imaging; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplastic process; noninvasive diagnosis; nuclear magnetic resonance spectroscopy; outcomes research; patient oriented research; prognosis

DESCRIPTION (provided by applicant): More than 55,000 Americans will develop cancer of the head and neck (HN) this year accounting for nearly 3% of all cancers in the United States. These cancers are more common in men and in people over age 50. More than 85% of these cancers are related to tobacco and alcohol consumption. Despite aggressive surgery and radiotherapy (RT), which may result in significant functional loss, the survival rate of patients with head and neck cancer has remained relatively unchanged over the past three decades. The predictive indices based on tumor morphology or clinical characteristics are generally less accurate in defining outcome of response. Hence, there is an urgent need for a reliable predictor of early response in these tumors. Magnetic resonance spectroscopy (MRS) and imaging (MRI) can non-invasively identify specific metabolic patterns and tissue physiology that may be used as markers for predicting and monitoring early treatment response. Preliminary studies on 41 cases of non-Hodgkins Lymphomas and 12 cases of HN tumors indicate that 31p MRS can predict response prior to initiation of therapy. 1H MRS and MRI provides higher sensitivity and spatial resolution than 31p MRS and would thus facilitate studying smaller tumors and investigating heterogeneous tumor response. The overall goal for this proposal is to test the hypothesis that NMR spectroscopy and imaging can predict and monitor early response to treatment of head and neck tumors. This hypothesis will be tested with the following specific aims: Aim 1: To evaluate the utility of the PME/13 NTP ratio in predicting and detecting treatment response by 31p MRS, Aim 2: To determine if total choline (Cho) and lactate (Lac) levels can predict and monitor treatment response and Aim 3: To use physiological MRI parameters (T2, ADC and DCE) as predictors/monitors of local tumor response to chemotherapy and radiation therapy of HN tumors. 31p MRS studies will be performed using proton decoupled and NOE enhanced 3D CSI sequence. 1H MRS studies will be performed by implementing a selective multi-quantum coherence transfer pulse sequence (Sel-MQC), for detection of lactate (Lac) and total choline (TCho) on the clinical scanner. Standard MRI pulse sequences for implementing dynamic contrast enhanced (DCE), diffusion weighted imaging (DWI) and T2 weighted imaging (T2WI) imaging will be streamlined so that a complete examination consisting of 31p MRS or 1H MRS combined with DCE, DWI and T2WI can be implemented on human HN patients within one hour.

描述（由申请人提供）： 今年，超过55,000名美国人将发展头颈癌（HN），占美国所有癌症的近3％。这些癌症在男性和50岁以上的人中更为普遍。这些癌症中有85％以上与烟草和饮酒有关。尽管攻击性手术和放疗（RT）可能导致功能性丧失，但在过去的三十年中，头颈癌患者的存活率仍然相对不变。基于肿瘤形态或临床特征的预测指标通常在定义反应结果时较少准确。因此，迫切需要这些肿瘤中可靠的早期反应预测指标。磁共振光谱（MRS）和成像（MRI）可以非侵入性地识别特定的代谢模式和组织生理学，可以用作预测和监测早期治疗反应的标志物。对41例非霍奇金斯淋巴瘤和12例HN肿瘤病例的初步研究表明，31p MRS可以在开始治疗之前预测反应。 1H MRS和MRI比31p MRS提供更高的敏感性和空间分辨率，因此将促进研究较小的肿瘤并研究异质性肿瘤反应。该提案的总体目标是检验NMR光谱和成像可以预测和监测对头颈肿瘤治疗的早期反应的假设。 This hypothesis will be tested with the following specific aims: Aim 1: To evaluate the utility of the PME/13 NTP ratio in predicting and detecting treatment response by 31p MRS, Aim 2: To determine if total choline (Cho) and lactate (Lac) levels can predict and monitor treatment response and Aim 3: To use physiological MRI parameters (T2, ADC and DCE) as predictors/monitors of local tumor response to chemotherapy and HN肿瘤的放射治疗。 31p MRS研究将使用质子解耦和NOE增强的3D CSI序列进行。 1H MRS研究将通过在临床扫描仪上实施选择性多量子相干转移脉冲序列（SEL-MQC），以检测乳酸（LAC）和总胆碱（TCHO）。用于实施动态对比增强（DCE），扩散加权成像（DWI）和T2加权成像（T2WI）成像的标准MRI脉冲序列将被简化，以便在一个小时内与DCE，DWI和T2WI结合的完整检查与DCE，DWI和T2WI结合在一起。